Drugs & Targets Foundation Medicine to develop companion diagnostics for Lilly’s Retevmo and Loxo Oncology at Lilly’s pipeline February 11, 2022Vol.48 No.06
Drugs & Targets FDA investigating possible increased risk of death with lymphoma drug Ukoniq February 04, 2022Vol.48 No.05
Drugs & Targets Veru, Eli Lilly to evaluate enobosarm + Verzenio in phase III ENABLAR-2 trial February 04, 2022Vol.48 No.05
Drugs & Targets FDA grants fast track designation for enobosarm in AR+ ER+ HER2- metastatic breast cancer January 14, 2022Vol.48 No.02
Drugs & Targets Carisma, Moderna to develop CAR-M therapies for cancer in $45M deal January 14, 2022Vol.48 No.02
Drugs & Targets Cullinan Oncology, Mount Sinai partner to advance novel small molecule immune modulators January 14, 2022Vol.48 No.02
Drugs & Targets FDA clears IND for P-MUC1C-ALLO1, a fully allogeneic CAR T targeting multiple solid tumors January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Breakthrough Therapy designation for CLN-081 in locally advanced or metastatic EGFR-mutated NSCLC January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Fast Track designation for Reqorsa with Keytruda in NSCLC January 07, 2022Vol.48 No.01
Drugs & Targets Rain Therapeutics, Roche to collaborate on clinical trial of milademetan combination with anti-PD-L1 immunotherapy for solid tumors January 07, 2022Vol.48 No.01
